FDA advisory panel recommends Covid shot update to target XFG variant, Pfizer agrees to $10.5 billion deal with Innovent Biologics, and Replimune drug seeks third FDA approval attempt.
As the week comes to a close, many are looking forward to a well-deserved break and some much-needed relaxation. The warmer weather is beckoning people to get outdoors and enjoy nature, whether that means hiking, walking, or simply taking a drive through the countryside. Alternatively, some may prefer to stay indoors and catch up on their favorite TV shows or try out a new recipe in the kitchen. Whatever the choice, it is essential to prioritize safety and make the most of the downtime.
The US Food and Drug Administration has been making headlines recently, with an advisory panel recommending an update to the Covid shots to target the XFG variant, also known as the "stratus" strain. This recommendation is intended to help vaccine manufacturers prepare for the fall and winter seasons, when Covid infections typically increase. The meeting was the agency's first since FDA Commissioner Marty Makary resigned, although his resignation did not play a role in the meeting, which was already scheduled.
In other news, Pfizer has agreed to a global licensing and collaboration deal with China's Innovent Biologics, worth up to $10.5 billion, to develop 12 early-stage cancer medicines. This deal is part of a larger trend of global drugmakers seeking to tap into China's booming biotech pipeline, with the value of such deals in the greater China region rising nearly tenfold from 2021 to an unprecedented $137.7 billion last year. The partnership will focus on developing antibody-drug conjugates and multi-specific antibodies, with eight assets originating from Innovent and four proposed by Pfizer.
The World Health Organization has identified several drugs that should be fast-tracked through clinical testing to respond to the current Ebola outbreak, including maftivimab from Regeneron Pharmaceutical, MBP134 from Mapp Bio, and remdesivir from Gilead Sciences. These drugs will be studied in patients infected with the Bundibugyo form of Ebola, which has currently infected over 1,000 people in the Democratic Republic of the Congo, with cases also reported in neighboring Uganda. The WHO has emphasized the need for urgent action to combat the outbreak, which has already led to 10 confirmed deaths and 223 suspected cases.
In addition to these developments, Replimune is seeking its third attempt at FDA approval for one of its drugs, highlighting the challenges and complexities of the pharmaceutical industry. As the industry continues to evolve, it is essential to stay informed about the latest developments and advancements in medical research and technology. With the FDA panel's recommendation, Pfizer's deal with Innovent Biologics, and the WHO's efforts to combat the Ebola outbreak, there is no shortage of important news and updates in the world of pharmaceuticals and healthcare.
